Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

1. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.Pediatric blood & cancer · 2013
   Trial
2. Integrative bioinformatics analysis and experimental validation identify CHEK1 as an unfavorable prognostic biomarker related to immunosuppressive phenotypes in soft tissue sarcomas.NPJ precision oncology · 2025
   Article
3. A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
   Article
4. Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?Virchows Archiv : an international journal of pathology · 2018
   Article
5. What is new in the biology and treatment of pediatric rhabdomyosarcoma?Current opinion in pediatrics · 2014
   Review
6. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma.PLoS genetics · 2014
   Article
7. Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.Skeletal muscle · 2012
   Article
8. The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012
   Review
9. Clinical utility gene card for: Alveolar rhabdomyosarcoma.European journal of human genetics : EJHG · 2012
   Article

Corrections and comments

• Comment on
  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.2010

Authors and funding

6 authors at 6 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as